Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Oncology Report

• Publication date

  2013-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3892/or.2013.2331PMID 23467984
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• Autophagy Inhibition Enhances Daunorubicin-Induced Apoptosis in K562 Cells

  2011cited by this paper
• The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

  2007cited by this paper
• Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

  2007cited by this paper
• Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation

  2007cited by this paper
• Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

  2007cited by this paper
• Sorafenib in advanced clear-cell renal-cell carcinoma.

  2007cited by this paper
• Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways

  2006cited by this paper
• The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions

  2006cited by this paper
• Oncogenic Ras in tumour progression and metastasis

  2005cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• Coordinating ERK/MAPK signalling through scaffolds and inhibitors

  2005cited by this paper
• Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

  2004cited by this paper
• Cancer genes and the pathways they control

  2004cited by this paper
• Protein kinase Cζ

  2002cited by this paper
• Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin.

  2001cited by this paper
• Signaling pathways activated by daunorubicin.

  2001cited by this paper
• The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors.

  2000cited by this paper
• Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells

  1997cited by this paper
• Functions of Ceramide in Coordinating Cellular Responses to Stress

  1996cited by this paper
• Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter.

  1996cited by this paper
• Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines.

  1996cited by this paper
• A signal transduction pathway for activation of the mdr1 promoter involves the proto-oncogene c-raf kinase.

  1993cited by this paper
• The molecular pharmacology of doxorubicin in vivo.

  1991cited by this paper
• Free radical production from normal and adriamycin-treated rat cardiac sarcosomes.

  1985cited by this paper

• Semisynthesis and biological evaluation of (+)-sclerotiorin derivatives as antitumor agents for the treatment of hepatocellular carcinoma.

  2022cites this paper
• A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells

  2019cites this paper
• Stavudine Reduces NLRP3 Inflammasome Activation and Upregulates Aβ-Autophagy

  2018cites this paper
• CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia

  2016cites this paper
• 13-Oxyingenol dodecanoate, a cytotoxic ingenol derivative, induces mitochondrial apoptosis and caspase-dependent Akt decrease in K562 cells

  2016cites this paper